GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...
$2 million grant builds on research to develop sequence elements that improve DNA- and RNA-based medicine efficacy Primrose Bio, Inc., a company with pr...
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property c...
Biocytogen and Whitehawk Therapeutics, Inc. announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytog...
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming imm...
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, announced that it h...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
First regulatory approval for iza-bren (BL-B01D1), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) Represents an important n...
New regional identity unites a more than $100 billion bioscience ecosystem and positions Indiana among the world's leading innovation hubs. BIO Internat...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, comes at a pivotal moment for emerging biotech companies. While scienti...
As biotech innovators pursue increasingly complex therapies, the path from discovery to clinical proof of concept is becoming more challenging than ever. F...
First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalati...
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including th...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any pr...
© 2026 Biopharma Boardroom. All Rights Reserved.
